贏合科技(300457.SZ):控股子公司深圳斯科爾從事電子煙業務
格隆匯6月26日丨有投資者向贏合科技(300457.SZ)提問,“目前市場擔憂鋰電池行業將出現產能過剩,請問貴司對此有何看法?貴司有沒有在鋰電池之外的業務佈局或戰略?”
贏合科技回覆稱,鋰電業務方面,公司在保持國內市場份額領先的情況下,將繼續加大海外市場的拓展力度,並積極把握新技術以及結構性需求增長帶來的發展機會。非鋰電業務方面,公司下屬控股子公司深圳市斯科爾科技股份有限公司從事電子煙業務。斯科爾自2022年開始大力發展自有品牌業務,憑藉產品和技術優勢,在英國及歐洲其他國家品牌業務取得了較好發展。此外,公司已在積極關注和研究一些新領域,力爭實現業務多元化發展,但目前暫時沒有確定具體將拓展的新領域。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.